Table 1 Demographic and baseline characteristics of the two patient groups before PSM (N = 903).

From: D-dimer, a predictor of bad outcome in gastric cancer patients undergoing radical resection

Characteristics

Total

NDG

EDG

P value

(N = 903)

(N = 742)

(N = 161)

Gender, no. (%)

   

0.041

Female

216(23.9)

167(22.5)

49(30.4)

 

Male

687(76.1)

575(77.5)

112(69.6)

 

Age ≥ 65 years, no. (%)

290(32.1)

211(28.4)

79(49.1)

 < 0.001

PT, second

13(12.5–13.5)

13(12.5–13.5)

13.1(12.6–13.7)

0.091

PTA, %

96.46 ± 17.25

96.91 ± 16.95

94 ± 18.67

0.096

PTR

1.02(0.98–1.07)

1.02(0.98–1.07)

1.02(0.99–1.08)

0.156

APTT, second

34.6(32–37.2)

34.55(32.1–37.33)

34.7(31.55–36.95)

0.382

INR

1.02(0.98–1.07)

1.02(0.98–1.07)

1.03(1–1.09)

0.012

TT, second

16.3(15.7–16.9)

16.3(15.8–16.9)

16.2(15.6–16.85)

0.333

FIB, g/l

3.2(2.64–3.8)

3.12(2.62–3.7)

3.44(2.81–4.2)

 < 0.001

D-dimer, mg/l

0.5(0.2–0.9)

0.4(0.1–0.6)

1.7(1.2–2.75)

 < 0.001

FDP, mg/l

1.1(0.6–1.83)

0.9(0.6–1.4)

3.2(2.3–5.4)

 < 0.001

Platelet

202(157–254)

202.5(157–255)

200(155.8–250.5)

0.77

Tumor location, no. (%)

   

0.992

Proximal stomach

294(32.6)

241(32.4)

53(32.9)

 

Distal stomach

478(52.9)

393(53)

85(52.8)

 

Total stomach

131(14.5)

108(14.6)

23(14.3)

 

T stage, no. (%)

   

 < 0.001

T1

190(21)

172(23.2)

18(11.2)

 

T2

76(8.4)

68(9.2)

8(5)

 

T3

153(16.9)

114(15.4)

39(24.2)

 

T4

484(53.6)

388(52.3)

96(59.6)

 

N stage, no. (%)

   

 < 0.001

N0

385(42.6)

334(45)

51(31.7)

 

N1

143(15.8)

122(16.4)

21(13)

 

N2

166(18.4)

138(18.6)

28(17.4)

 

N3

209(23.1)

148(19.9)

61(37.9)

 

TNM stage, no. (%)

   

 < 0.001

I

223(24.7)

199(26.8)

24(14.9)

 

II

149(16.5)

130(17.5)

19(11.8)

 

III

531(58.8)

413(55.7)

118(73.3)

 

Chemotherapy

   

0.053

Yes

546(60.5)

456(61.5)

112(69.6)

 

No

335(37.1)

286(38.5)

49(30.4)

 

Histology, no. (%)

   

0.78

Differentiated

289(32)

236(31.8)

53(32.9)

 

Undifferentiated

614(68)

506(68.2)

108(67.1)

 

OS, month

37(19–59)

39(24–61)

19(10–42.5)

 < 0.001

DFS, month

37(18–59)

39(23–61)

18.5(9–43.25)

 < 0.001

LNR

0.07(0–0.31)

0.05(0–0.28)

0.21(0–0.56)

 < 0.001

Tumor size, cm

4(2.5–5.5)

4(2.5–5.5)

4.5(3–6)

0.005

  1. Abbreviations: PSM, Propensity Score Matching; NDG, normal D-dimer group (< 1 mg/l); EDG, elevated D-dimer group (≥ 1 mg/l); PT, prothrombin time; PTA, prothrombin activity; PTR, prothrombin ratio; APTT, activated partial prothrombin time; INR, international normalized ratio; TT, thrombin time; FIB, fibrinogen; FDP, fibrin degradation products; TNM, Tumor-node-metastasis; OS, overall survival; DFS, disease free survival; LNR, Lymph node ratio.